Lasting Outcome Similar for ULS, SSLF for Pelvic Organ Prolapse
TUESDAY, April 17, 2018 -- For women with pelvic organ prolapse, there is no significant difference in five-year outcomes with uterosacral ligament suspension (ULS) and sacrospinous ligament fixation (SSLF) surgeries, and no difference in the success of perioperative behavioral therapy and pelvic floor muscle training (BPMT) or usual care, according to a study published in the April 17 issue of the Journal of the American Medical Association.
J. Eric Jelovsek, M.D., from the Cleveland Clinic, and colleagues conducted a 2 × 2 factorial randomized clinical trial at nine U.S. medical centers. Women were randomized to BPMT or usual care (186 and 188 women, respectively), or to surgical interventions: ULS or SSLF (188 and 186 women, respectively).
The researchers found that the estimated surgical failure rate was 61.5 and 70.3 percent in the ULS and SSLF groups, respectively (adjusted difference, −8.8 percent; 95 percent confidence interval, −24.2 to 6.6), by year five. The estimated anatomic failure rate was 45.6 and 47.2 percent in the BPMT and usual care groups, respectively (adjusted difference, −1.6 percent; 95 percent confidence interval, −21.2 to 17.9). Improvements in the Pelvic Organ Prolapse Distress Inventory scores were −59.4 and −61.8 in the BPMT and usual care groups, respectively (adjusted mean difference, 2.4; 95 percent confidence interval, −13.7 to 18.4).
"Compared with outcomes at two years, rates of surgical failure increased during the follow-up period, although prolapse symptom scores remained improved," the authors write.
Several authors disclosed financial relationships with UpToDate.
© 2020 HealthDay. All rights reserved.
Posted: April 2018
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.